Immune checkpoint inhibitors for endometrial and cervical cancer

• Date : 2021-10-25
• 10    
  0

Gynecological cancer care in the UK

• Date : 2021-10-25
• 5    
  0

What to look forward to at ESGO 2021?

• Date : 2021-10-25
• 2    
  0

Telemedicine in the COVID-19 pandemic: advantages and challenges

• Date : 2021-10-25
• 1    
  0

Practical management of urological and intestinal complications

• Date : 2021-10-25
• 1    
  0

ESGO perioperative guidelines for ovarian cancer surgery

• Date : 2021-10-25
• 1    
  0

ENGOT-EN1: carboplatin plus paclitaxel plus nintedanib for endometrial cancer

• Date : 2021-10-25
• 0    
  0

European Society of Gynaecological Oncology 2021 Congress

• Date : 2021-10-25
• 0    
  0

Eductional highlights from ESGO 2021

• Date : 2021-10-25
• 0    
  0

What womens health means for women's cancers

• Date : 2021-10-25
• 0    
  0

Chemotherapy vs. palliative care for patients with ovarian cancer

• Date : 2021-10-25
• 0    
  0

Highlights of ESGO 2021 for young researchers

• Date : 2021-10-25
• 0    
  0

Molecular classification and adjuvant treatment in endometrial cancer

• Date : 2021-10-25
• 0    
  0

Role of palliative surgery in ovarian cancer

• Date : 2021-10-25
• 0    
  0

How to improve standard operating procedures for gynecological cancer management

• Date : 2021-10-25
• 0    
  0

Gynecological cancers: co-morbidities and best supportive care

• Date : 2021-10-25
• 0    
  0

Breaking bad news in oncology

• Date : 2021-10-25
• 0    
  0

KEYNOTE-826: pembrolizumab + chemotherapy vs placebo + chemotherapy for cervical cancer

• Date : 2021-10-25
• 0    
  0

Importance of pathology in gynecological cancer

• Date : 2021-10-25
• 0    
  0

Pathologic risk stratification of gynecological cancer

• Date : 2021-10-25
• 0    
  0

Highlights for pathology at ESGO

• Date : 2021-10-25
• 0    
  0

Gestational trophoblastic tumors

• Date : 2021-10-25
• 0    
  0

TROPHIMMUN: Results of avelumab for patients with chemo-resistant gestational trophoblastic tumors

• Date : 2021-10-25
• 0    
  0

Non-invasive prenatal testing for cancer diagnosis

• Date : 2021-10-25
• 0    
  0

Multidisciplinary approach for diagnosing cancer in pregnant women

• Date : 2021-10-25
• 0    
  0

Endometrial Cancer Health Outcomes: pembrolizumab for patients with MSI-high endometrial cancer

• Date : 2021-10-25
• 0    
  0

Importance of real-world data on patient outcomes

• Date : 2021-10-25
• 0    
  0

Challenges in treatment of obese patients with gynecological malignancies

• Date : 2021-10-25
• 0    
  0

Advances in telemedicine for surgeons

• Date : 2021-10-25
• 0    
  0

ENYGO: aims and resources for gynecologic fellows

• Date : 2021-10-25
• 0    
  0

ENYGO: network of young gynecologic oncologists

• Date : 2021-10-25
• 0    
  0

Impact of the COVID-19 pandemic on surgery in patients with gynecologic malignancies in the UK

• Date : 2021-10-25
• 0    
  0

Preoperative diagnosis of ovarian masses

• Date : 2021-10-25
• 0    
  0

Improving patient stratification in patients with ovarian masses

• Date : 2021-10-25
• 0    
  0

Significance of surgical assessment on outcomes after radical hysterectomy for cervical cancer

• Date : 2021-10-25
• 0    
  0

Highlights from ESGO 2021

• Date : 2021-10-25
• 0    
  0

Robotics in surgical cervical cancer treatment

• Date : 2021-10-25
• 0    
  0

Precision oncology in endometrial cancer

• Date : 2021-10-25
• 0    
  0

Importance of understanding molecular subtypes in endometrial cancer

• Date : 2021-10-25
• 0    
  0

Should 1L maintenance with PARP inhibitors be given to all patients with ovarian cancer?

• Date : 2021-10-25
• 0    
  0

Regional challenges in gynaecological cancer and access to care

• Date : 2021-10-25
• 0    
  0

Hudson-Dellepiane procedure

• Date : 2021-10-25
• 0    
  0

Immune checkpoint inhibitors in ovarian cancer

• Date : 2021-10-25
• 0    
  0

Novel immunotherapy-based combination approaches in cervical cancer

• Date : 2021-10-25
• 0    
  0

Future of precision medicine in endometrial cancer

• Date : 2021-10-25
• 0    
  0

PARP inhibitor rechallenging in ovarian cancer

• Date : 2021-10-25
• 0    
  0

Results from the JAVELIN Ovarian 200 biomarker analysis

• Date : 2021-10-25
• 0    
  0

Impact of COVID-19 on the training and mental well-being of surgical gynecological oncology trainees

• Date : 2021-10-25
• 0    
  0

Improving immunotherapy outcomes in ovarian cancer

• Date : 2021-10-25
• 0    
  0

Durvalumab and oleclumab in patients with relapsed ovarian cancer

• Date : 2021-10-25
• 0    
  0

Gender challenges in gynecologic oncology

• Date : 2021-10-25
• 0    
  0

KORE Innovation trial: an enhanced perioperative pathway for patients with ovarian cancer

• Date : 2021-10-25
• 0    
  0

Next steps in improving access to therapies

• Date : 2021-10-25
• 0    
  0

Personalized medicine for patients with gynecological sarcoma

• Date : 2021-10-25
• 0    
  0

27ᵉ Congrès Européen d'Oncologie Gynécologique de l'ESGO

• Date : 2026-02-26
• 100    
  0

34ᵉ Conférence Annuelle de la Société Européenne d'Endoscopie Gynécologique - ESGE 2025

• Date : 2025-10-19
• 2422    
  0

25ème Journée Nationale du GEDO

• Date : 2025-10-16
• 691    
  0

15e Congrès Mondial de Gynécologie et d'Obstétrique de la FIGO 2025

• Date : 2025-10-05
• 1673    
  0

INFOGYN 2025

• Date : 2025-10-02
• 1352    
  0